Skip to content

A randomized, double-blind, controlled trial of shenjingfuyuanfang for the prevention of recurrence of mild ischemic stroke

A randomized, double-blind, controlled trial of shenjingfuyuanfang for the prevention of recurrence of mild ischemic stroke

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040010
Enrollment
Unknown
Registered
2020-11-18
Start date
2020-11-05
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Chinese traditional medicine group:shenjingfuyuanfang granules
The control group:shenjingfuyuanfang Granule emulsions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for ischemic stroke; (2) Meet the above definition of mild stroke; (3) TCM syndrome differentiation is consistent with deficiency of Qi and Yin and block of phlegm and blood stasis; (4) 40 ~ 80 years old; (5) Between 3 weeks and 3 months after onset; (6) Patients' informed consent.

Exclusion criteria

Exclusion criteria: (1) Under the age of 40 or over 80; A pregnant or lactating woman; (2) Exclude atherosclerotic stroke, cardiac stroke and stroke caused by vascular malformation, infection, rheumatic immune disease and other causes; (3) Patients with aspirin contraindications, such as thrombocytopenia, gastrointestinal ulcer, hemorrhagic disease, asthma, etc.; (4) Patients with contraindications of statins, such as abnormal liver function and elevated creatine kinase; (5) Before enrollment, the control of risk factors such as blood pressure and blood sugar basically reaches the standard; (6) Patients with heart, liver, kidney hematopoietic system and other serious primary diseases and psychosis; (7) Epilepsy, brain tumor, Parkinson's disease and other severe neurological diseases.

Design outcomes

Primary

MeasureTime frame
NIHSS???;Drinking water test;Improved Rankin Rating (mRS);

Countries

China

Contacts

Public ContactWentao Li

Shanghai Municipal Hospital of Traditional Chinese Medicine

lwt1132@163.com+86 13331882730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026